title: Oxidative stress and aminopeptidases in Parkinson's disease patients with and without treatment.
abstract: OBJECTIVE
  Mitochondrial dysfunction, oxidative stress and protein metabolism impairment are the main molecular events underlying the pathogenesis of Parkinson's disease (PD). However, only few studies have addressed the changes produced by these phenomena in the blood of PD patients. Our purpose was to compare oxidative stress between newly diagnosed PD patients (ntPD) and PD patients under treatment (tPD). We also analyzed changes in plasma activity of several aminopeptidases (AP) involved in the metabolism of various active peptides.
  
  
  METHODS
  Plasma lipid peroxide (LPO) and lactate (LAC) concentrations were measured by colorimetric methods, and plasma AP activities were determined by fluorometric assay.
  
  
  RESULTS
  LPO and LAC concentrations were significantly elevated in ntPD and tPD patients versus controls, but there were no differences between the PD groups. Alanine-, cystine- and aspartate-AP activities were significantly lower in tPD versus ntPD patients. Nondenaturing electrophoresis and Western blot results confirmed these findings.
  
  
  CONCLUSIONS
  The plasma LPO and LAC levels were high in both PD groups, indicating that they are elevated at an early stage of PD and are not affected by anti-PD treatment. The higher AP activities in ntPD versus tPD patients suggest that anti-PD treatment may improve protein metabolism while not altering oxidative stress. A therapy directed to reduce oxidative stress and normalize AP activity may be useful in the treatment of PD.
authors: Department of Physiology and Institute of Neurosciences, Centro de Investigaciones Biomedicas, University of Granada, Granada, Spain.
authors: Raquel
authors: R
authors: Duran
authors: Francisco J
authors: FJ
authors: Barrero
authors: Blas
authors: B
authors: Morales
authors: Juan D
authors: JD
authors: Luna
authors: Manuel
authors: M
authors: Ramirez
authors: Francisco
authors: F
authors: Vives
mesh_terms: D000368:Aged; D000626:Aminopeptidases / Q000097:blood*; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002230:Carbidopa / Q000627:therapeutic use; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007773:Lactates / Q000097:blood; D007980:Levodopa / Q000627:therapeutic use; D008054:Lipid Peroxides / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000502:physiology*; D010300:Parkinson Disease / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D000978:Antiparkinson Agents; D007773:Lactates; D008054:Lipid Peroxides; D008055:Lipids; D007980:Levodopa; D000626:Aminopeptidases; D002230:Carbidopa